Immunotherapy and targeted therapy before surgery for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether combining two drugs, adebrelimab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that blocks blood supply to tumors), before surgery can improve outcomes for people with early-stage non-small cell lung cancer. The goal is to shrink the tumor and make surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with stage II, IIIA, or selected stage IIIB non-small cell lung cancer that can be removed with surgery.
- You have not had any prior cancer treatment for this disease.
- Your tumor tests positive for PD-L1 (a protein that helps cancer hide from the immune system) at a level of at least 1%.
- You are in good overall health, with adequate organ function (heart, lungs, liver, kidneys) and an ECOG performance status of 0 or 1 (meaning you are fully active or only limited in strenuous activity).
- You do not have distant metastases (cancer that has spread to other parts of the body).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining an immunotherapy drug (adebrelimab or retlirafusp alfa) with another drug (recaticimab) and chemotherapy helps shrink lung cancer before surgery. The goal is to see if this approach improves outcomes for people with resectable non-small cell lung cancer.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests a new drug combined with other treatments for people with lung cancer that can be removed by surgery. It aims to see if the treatment shrinks tumors before surgery and improves outcomes.
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
This trial tests whether giving a combination of an immunotherapy drug (adebrelimab) and chemotherapy before surgery can shrink tumors better in lung cancer that has certain genetic changes. The hope is that this pre-surgery treatment will improve outcomes.
This trial tests whether giving two immunotherapy drugs directly into the tumor before surgery can shrink non-small cell lung cancer and improve outcomes. It is for people with early-stage (IIIA) lung cancer who are candidates for surgery.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.